Cargando…
Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy
BACKGROUND: Conversion surgery is a treatment that aims for R0 resection of primary advanced gastric cancers (GCs) that have responded well to systemic chemotherapy. We investigated the role of conversion therapy in initially unresectable metastatic cancer with positive HER2 status that responded to...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372222/ https://www.ncbi.nlm.nih.gov/pubmed/35966292 http://dx.doi.org/10.21037/tcr-21-2886 |
_version_ | 1784767332995825664 |
---|---|
author | Zhang, Yanqiang Xu, Xiaoqing Hu, Can Du, Yian Ding, Guangyu Chen, Jiahui Zhu, Xiu Xu, Zhiyuan Wei, Qing |
author_facet | Zhang, Yanqiang Xu, Xiaoqing Hu, Can Du, Yian Ding, Guangyu Chen, Jiahui Zhu, Xiu Xu, Zhiyuan Wei, Qing |
author_sort | Zhang, Yanqiang |
collection | PubMed |
description | BACKGROUND: Conversion surgery is a treatment that aims for R0 resection of primary advanced gastric cancers (GCs) that have responded well to systemic chemotherapy. We investigated the role of conversion therapy in initially unresectable metastatic cancer with positive HER2 status that responded to chemotherapy plus trastuzumab. METHODS: A total of 32 metastatic GC patients who underwent systemic chemotherapy plus trastuzumab sequenced by conversion surgery at Zhejiang Cancer Hospital between 2015 and 2020 were retrospectively reviewed. RESULTS: The observed overall survival (OS) and progression-free survival (PFS) for all the patients were 30.2 and 25.1 months, respectively. The 1-year survival rate was 81.25%, and the 1-year PFS rate was 78.13%. Univariate and multivariate analyses demonstrated that liver metastasis (P=0.021), peritoneal metastasis (P=0.047), para-aortic lymph node metastasis (16a1/b2) (P=0.048), macroscopic type 4 (P=0.027), number of noncurative factors (P=0.011), Yoshida et al. category (P=0.021), and inductive chemotherapy cycles (P=0.025) were independent prognostic factors for OS. CONCLUSIONS: HER2-positive patients with potentially resectable disease had a remarkably good prognosis after conversion gastrectomy following trastuzumab treatment. Adequate selection of metastatic GC patients for conversion surgery is recommended. |
format | Online Article Text |
id | pubmed-9372222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-93722222022-08-13 Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy Zhang, Yanqiang Xu, Xiaoqing Hu, Can Du, Yian Ding, Guangyu Chen, Jiahui Zhu, Xiu Xu, Zhiyuan Wei, Qing Transl Cancer Res Original Article BACKGROUND: Conversion surgery is a treatment that aims for R0 resection of primary advanced gastric cancers (GCs) that have responded well to systemic chemotherapy. We investigated the role of conversion therapy in initially unresectable metastatic cancer with positive HER2 status that responded to chemotherapy plus trastuzumab. METHODS: A total of 32 metastatic GC patients who underwent systemic chemotherapy plus trastuzumab sequenced by conversion surgery at Zhejiang Cancer Hospital between 2015 and 2020 were retrospectively reviewed. RESULTS: The observed overall survival (OS) and progression-free survival (PFS) for all the patients were 30.2 and 25.1 months, respectively. The 1-year survival rate was 81.25%, and the 1-year PFS rate was 78.13%. Univariate and multivariate analyses demonstrated that liver metastasis (P=0.021), peritoneal metastasis (P=0.047), para-aortic lymph node metastasis (16a1/b2) (P=0.048), macroscopic type 4 (P=0.027), number of noncurative factors (P=0.011), Yoshida et al. category (P=0.021), and inductive chemotherapy cycles (P=0.025) were independent prognostic factors for OS. CONCLUSIONS: HER2-positive patients with potentially resectable disease had a remarkably good prognosis after conversion gastrectomy following trastuzumab treatment. Adequate selection of metastatic GC patients for conversion surgery is recommended. AME Publishing Company 2022-07 /pmc/articles/PMC9372222/ /pubmed/35966292 http://dx.doi.org/10.21037/tcr-21-2886 Text en 2022 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Zhang, Yanqiang Xu, Xiaoqing Hu, Can Du, Yian Ding, Guangyu Chen, Jiahui Zhu, Xiu Xu, Zhiyuan Wei, Qing Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy |
title | Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy |
title_full | Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy |
title_fullStr | Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy |
title_full_unstemmed | Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy |
title_short | Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy |
title_sort | trastuzumab in combination with chemotherapy for her2-positive metastatic gastric cancer patients underwent conversion therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372222/ https://www.ncbi.nlm.nih.gov/pubmed/35966292 http://dx.doi.org/10.21037/tcr-21-2886 |
work_keys_str_mv | AT zhangyanqiang trastuzumabincombinationwithchemotherapyforher2positivemetastaticgastriccancerpatientsunderwentconversiontherapy AT xuxiaoqing trastuzumabincombinationwithchemotherapyforher2positivemetastaticgastriccancerpatientsunderwentconversiontherapy AT hucan trastuzumabincombinationwithchemotherapyforher2positivemetastaticgastriccancerpatientsunderwentconversiontherapy AT duyian trastuzumabincombinationwithchemotherapyforher2positivemetastaticgastriccancerpatientsunderwentconversiontherapy AT dingguangyu trastuzumabincombinationwithchemotherapyforher2positivemetastaticgastriccancerpatientsunderwentconversiontherapy AT chenjiahui trastuzumabincombinationwithchemotherapyforher2positivemetastaticgastriccancerpatientsunderwentconversiontherapy AT zhuxiu trastuzumabincombinationwithchemotherapyforher2positivemetastaticgastriccancerpatientsunderwentconversiontherapy AT xuzhiyuan trastuzumabincombinationwithchemotherapyforher2positivemetastaticgastriccancerpatientsunderwentconversiontherapy AT weiqing trastuzumabincombinationwithchemotherapyforher2positivemetastaticgastriccancerpatientsunderwentconversiontherapy |